Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31901 in Advanced Malignant Tumors
NCT04954456Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of QLS31901 in cancer (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Safety and tolerability at 21 days. Status: unknown.
02
Drugs
QLS31901
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04954456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954456.